Janus Henderson Group
FULC icon

Janus Henderson Group’s Fulcrum Therapeutics FULC Stock Holding History

Janus Henderson Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,972
Closed -$54K – 2626
2023
Q1 		$54K Buy
+18,972
New +$170K ﹤0.01% 2657
2021
Q1 		– Sell
-229,634
Closed -$2.69M – 1579
2020
Q4 		$2.69M Buy
229,634
+52,468
+30% +$593K ﹤0.01% 1080
2020
Q3 		$1.4M Buy
+177,166
New +$2.13M ﹤0.01% 1107

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group's FULC Position: Q2 2023 in Review

Janus Henderson Group sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 18,972 shares — an estimated $54K sold.

Janus Henderson Group first reported a position in FULC in Q3 2020 and held it in 3 quarters. The position peaked at $2.69M in Q4 2020. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Janus Henderson Group reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 18,972 Fulcrum Therapeutics shares in Q2 2023, an estimated $54K.
  • Janus Henderson Group first reported a position in Fulcrum Therapeutics in Q3 2020 and held it in 3 quarters.
  • Janus Henderson Group's Fulcrum Therapeutics position peaked at $2.69M in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.